Pridopidine Modulation of Motor Activity in Rett Syndrome Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are ineffective for Rett syndrome, a neurological disorder characterized by incoordination, intellectual decline, and seizures, with no available therapy to manage symptoms such as partial or complete loss of mobility skills, muscle weakness, and abnormal muscle tone.
Innovation Solution
A composition comprising pridopidine or its pharmaceutically acceptable salts, administered via various routes and forms, including oral, nasal, and injectable forms, to delay symptom onset, prevent worsening, or improve symptoms like muscle weakness and abnormal muscle tone.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no treatment is available for Rett syndrome, then the disease progresses with severe symptoms including loss of mobility skills, muscle weakness, and abnormal muscle tone, but introducing a new drug treatment requires extensive preclinical validation to ensure safety and efficacy
Solution Approach 1:
The patent performs preliminary actions by conducting extensive preclinical studies in multiple animal models (Rett syndrome mouse models, Huntington's disease models) before human trials. The drug's pharmacological profile, neuroprotective effects, and motor activity modulation are established in advance through rigorous animal testing, creating a foundation for subsequent clinical evaluation.
Solution Approach 2:
The patent incorporates feedback mechanisms by measuring multiple parameters including BDNF expression levels, motor coordination tests, gait analysis, and behavioral assessments in animal models. This comprehensive feedback system allows optimization of dosing regimens and validation of therapeutic effects before proceeding to human clinical trials.
2Adaptability or versatility
If pridopidine is developed for Huntington's disease, then motor activity modulation and neuroprotection are achieved, but extending indication to Rett syndrome requires additional clinical trials and regulatory approval
Solution Approach 1:
The patent applies universality by demonstrating pridopidine's multi-functional properties across different neurological disorders. The drug's ability to modulate motor activity and provide neuroprotection in both Huntington's disease and Rett syndrome models establishes its versatile therapeutic potential, allowing a single compound to address multiple conditions through shared pathophysiological mechanisms.
Solution Approach 2:
The patent performs preliminary validation in Rett syndrome animal models before initiating formal clinical trials, leveraging existing pharmacological data from Huntington's disease studies. This preliminary characterization of efficacy and safety in RTT-specific models accelerates the transition to human trials by reducing uncertainty and informing trial design.
3Ease of operation
If pridopidine modulates motor activity by suppressing hyperactivity or enhancing hypoactivity, then motor function improves, but determining optimal dosing requires careful pharmacological characterization
Solution Approach 1:
The patent systematically varies dosing parameters including dose amount, frequency, and duration across multiple studies in animal models. By examining the relationship between dose parameters and motor function outcomes, the patent identifies optimal dosing regimens that maximize therapeutic benefit while minimizing adverse effects, establishing a evidence-based dosing strategy for clinical translation.
Data Source
Figure 1
Figure 2~3
Figure 4~5
AI summary
A composition comprising pridopidine or its pharmaceutically acceptable salt for use in treating a subject afflicted with Rett syndrome (RTT), wherein the composition treats the subject by delaying the onset, preventing worsening, delaying worsening or improving at least one RTT symptom in the subject.